Harvard Bioscience Inc. logo

HBIO

Harvard Bioscience Inc.

$3.23

Earnings Summary

Revenue
$29.21Mn
Net Profits
$2.44Mn
Net Profit Margins
8.34%

Highlights

Revenue:

Harvard Bioscience Inc.’s revenue jumped 0.04% since last year same period to $29.21Mn in the Q2 2022. On a quarterly growth basis, Harvard Bioscience Inc. has generated 1.49% jump in its revenue since last 3-months.

Net Profits:

Harvard Bioscience Inc.’s net profit jumped 693.9% since last year same period to $2.44Mn in the Q2 2022. On a quarterly growth basis, Harvard Bioscience Inc. has generated 135.39% jump in its net profits since last 3-months.

Net Profit Margins:

Harvard Bioscience Inc.’s net profit margin jumped 693.68% since last year same period to 8.34% in the Q2 2022. On a quarterly growth basis, Harvard Bioscience Inc. has generated 134.87% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Harvard Bioscience Inc. post its latest quarter earnings

EPS Estimate Current Quarter
0.06
EPS Estimate Current Year
0.06

Highlights

EPS Estimate Current Quarter:

Harvard Bioscience Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.06 - a 20% jump from last quarter’s estimates.

EPS Estimate Current Year:

Harvard Bioscience Inc.’s earning per share (EPS) estimates for the current year stand at 0.06.

Key Ratios

Key ratios of the Harvard Bioscience Inc. post its Q2 2022 earnings

Return on Assets (ROA)
-0.01
Return on Equity (ROE)
-0.05
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Harvard Bioscience Inc.’s return on assets (ROA) stands at -0.01.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Harvard Bioscience Inc.’s return on equity (ROE) stands at -0.05.

Dividend Per Share (DPS):

Harvard Bioscience Inc. declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
0.05
0.04
-20%

Company Information

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned academic institutions and government laboratories, to the world's leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, the company sells through a combination of direct and distribution channels to customers around the world.

Organisation
Harvard Bioscience Inc.
Headquarters
Holliston, Massachusetts, US
Employees
444
Industry
Health Technology